Department of Radiology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Department of Radiology, Cincinnati Children's Hospital Medical Center, University of Cincinnati Medical Center, Cincinnati, OH, USA.
Pediatr Radiol. 2020 Jun;50(7):882-897. doi: 10.1007/s00247-020-04688-z. Epub 2020 Jun 3.
In recent years, new somatostatin receptor agents (SSTRs) have become available for diagnostic imaging and therapy in neuroendocrine tumors. The novel SSTR ligand DOTA-DPhel-Tyr3-octreotate (Dotatate) in particular can be linked with Gallium for diagnostic imaging purposes, and with the β-emitter Lutetium for radiotherapy in the setting of neuroendocrine tumors. Dotatate imaging offers distinct advantages in the evaluation of neuroendocrine tumors compared to standard techniques, including greater target-to-background ratio and lesion conspicuity, high sensitivity/specificity, improved spatial resolution with positron emission tomography (PET)/CT or PET/MR, and decreased radiation exposure. Although currently off-label in pediatrics, Dotatate theranostics in children are being explored, most notably in the setting of neuroblastoma and hereditary neuroendocrine syndromes. This article provides a multicenter case series of Dotatate imaging and therapy in pediatric patients in order to highlight the spectrum of potential clinical applications.
近年来，新的生长抑素受体配体（SSTRs）已可用于神经内分泌肿瘤的诊断成像和治疗。新型 SSTR 配体 DOTA-DPhel-Tyr3-octreotate（Dotatate）尤其可与镓结合用于诊断成像，并与β发射器镥结合用于神经内分泌肿瘤的放射治疗。与标准技术相比，Dotatate 成像在神经内分泌肿瘤的评估中具有明显的优势，包括更高的靶标与背景比和病变显著性、更高的敏感性/特异性、正电子发射断层扫描（PET）/CT 或 PET/MR 改善的空间分辨率，以及减少辐射暴露。尽管目前在儿科领域属于超适应证使用，但正在探索儿童的 Dotatate 治疗，特别是在神经母细胞瘤和遗传性神经内分泌综合征的治疗中。本文提供了多中心的儿科患者 Dotatate 成像和治疗的病例系列，以突出其潜在的临床应用范围。
